FirsthandHealth
medRxiv PreprintsInternational17 November 2026

Safety of Bio-Interventional Uveoscleral Outflow Enhancement: Twelve-Month Post-Operative Results from 395 Eyes in the CREST Study

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

PurposeTo characterize 12-month ocular safety of bio-interventional uveoscleral outflow enhancement in open-angle glaucoma (OAG). DesignProspective, multicenter real-world evidence study (CREST; NCT05506423). ParticipantsAdults with OAG treated by bio-interventional uveoscleral outflow enhancement with acellular scleral allograft spacers (AlloFlo, Iantrek, Inc.), standalone or with phacoemulsification, reaching 12 months of follow-up. MethodsAdverse events were captured prospectively at each protocol-specified visit against pre-defined definitions; data were analyzed at the eye level. Main Out
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.